Key clinical point: The combination of bevacizumab and pembrolizumab demonstrated acceptable safety and activity in patients with metastatic renal cell carcinoma.

Major finding: Responses occurred in 41.7% of relapsed/refractory patients in the phase 1b portion of the trial and in 60.9% of previously untreated patients in phase 2.

Study details: A phase 1b trial of 13 patients and phase 2 expansion study of 48 patients with metastatic clear cell renal cell carcinoma.

Disclosures: The study was funded by Merck. The authors disclosed financial affiliations with Merck and other companies.